Navigation Links
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Date:12/2/2009

Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About KRX-0401 (Perifosine)

KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically importa
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources ... awareness of the U.S. Food and Drug Administration,s (FDA) ... phosphate binder Velphoro, which was approved by the FDA ... chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... N.Y. , July 6 E. Fougera & ... first generic approval from the FDA for Adapalene Cream 0.1% ... to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. ... $55 million . This approval also marks the fourth product ...
... PARSIPPANY, N.J. , July 6 July 5th is ... in the state of Wisconsin and every year almost 7,200 of them ... an added incentive to quit with the Wisconsin smoke free law that ... , , ...
Cached Medicine Technology:Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin® 2Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin® 3Wisconsin Statewide Smoke-Free Law May Prompt Smokers to Quit 2Wisconsin Statewide Smoke-Free Law May Prompt Smokers to Quit 3
(Date:7/14/2014)... EurekaMag.com has newly published results of ... contagious liver disease that ranges in severity from ... serious, lifelong illness that attacks the liver. An estimated ... Hepatitis C virus infection of which approximately 80% of ... category covers all studies on Hepatitis C , the ...
(Date:7/14/2014)... "Medical devices, tests, and treatments are critical ... is a star when it comes to innovations in ... working on amazing products and ideas that are our ... to Dale Kaye CEO of the Innovation Tri-Valley ... brilliant minds and businesses that are leading society into ...
(Date:7/14/2014)... WI (PRWEB) July 14, 2014 Doctor ... announced the launch of their new company website. The ... valuable free information on chiropractic marketing. It's also a ... that Inception has to offer. , When contacted at ... the newest version of our main website. Our site ...
(Date:7/14/2014)... Essex, CT (PRWEB) July 14, 2014 Summer ... means vacations, camping, days at the beach, swimming and other ... want everyone to be safe, happy and healthy all summer ... of a list of the three must-have custom imprinted products ... first summer essential is of course sunblock. Sunscreen ...
(Date:7/13/2014)... 2014 Save the Date for the 2014 ... Jacksonville, FL , BOXWOODS & BowTies “A Modern Twist on ... The Women’s Board of Wolfson Children’s Hospital will ... to continue their ongoing commitment to raising funds for the ... , What: The 2014 Art & Antiques Show is a ...
Breaking Medicine News(10 mins):Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Doctor Mike Hamilton From Inception Chiropractic Websites Announces the Launch of Their New Website 2Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 2Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 3Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 4Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 5Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 6Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 7Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 8Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 9
... 21 LUMEDX Corporation, a leading,provider of ... introduces software to manage data and track ... Module empowers clinicians,by making critical clinical information ... For more information -- including a free ...
... May 20 The U.S. Department of,Health and ... advertising,campaign focusing on the quality of care available ... HHS, Centers for Medicare & Medicaid Services (CMS),in ... newspapers, promote Hospital,Compare ( http://www.hospitalcompare.hhs.gov ), an easy-to-use ...
... researchers,found that the frequency with which critically-ill patients ... a,multidisciplinary medical center such as Mayo Clinic compared ... the National Healthcare Safety,Network (NHSN). This is good ... are generally strong across the U.S. in intensive ...
... 2008) A newly published study presents data ... (COPD), including emphysema and chronic bronchitis, experienced markedly ... a combination of nebulized formoterol fumarate inhalation solution ... treatment with tiotropium alone. The two medications, ...
... BEDFORD, Mass., May 20 Hologic, Inc. (Nasdaq:,HOLX) today ... at the NASDAQ 21st Investor Program being held May ... parties are invited to listen to a live audio ... at 10:45 a.m.,BST on the investor section of the ...
... One of 35,000 Doctors Now Using E-Prescribing, ... (PCMA) is unveiling a new print ad campaign ... successfully use electronic,prescribing (e-prescribing) technology and who also ... new ad features Dr. R. David Allard, a ...
Cached Medicine News:Health News:New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 2Health News:National Ad Campaign Highlights Patient Ratings For More Than 1,000 Local U.S. Hospitals 2Health News:National Ad Campaign Highlights Patient Ratings For More Than 1,000 Local U.S. Hospitals 3Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 2Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 3Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 4Health News:PCMA's New Ad Campaign: E-Prescribing is Ready Now 2
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
10L...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: